Advertisement
VIR vs ZURA
Which Stock Would AI Choose? Vir Biotechnology (VIR) vs. Zura Bio (ZURA) Stock Comparison
Key Takeaways
- VIR has recently pivoted to a rare quarterly profit, driven by collaboration revenue from its Astellas and Gilead partnerships, while ZURA remains pre-revenue with a widening net loss.
- Both are clinical-stage biotechnology companies, but VIR pursues infectious-disease and oncology programs, whereas ZURA focuses on autoimmune and inflammatory disorders.
- VIR carries a larger market capitalization and a substantial cash position near $1 billion, giving it greater near-term financial flexibility than ZURA.
- ZURA is heavily concentrated around a single lead asset, tibulizumab, making its valuation more sensitive to a few upcoming Phase 2 data readouts.
- Analyst sentiment is broadly positive on both names, with each stock holding a "Strong Buy" consensus, though the two trade at very different stages of pipeline maturity.
Introduction
Vir Biotechnology and Zura Bio operate in the same broad healthcare universe but follow sharply different clinical roadmaps. This stock comparison is useful for growth-oriented investors weighing two development-stage biotechs with distinct risk-reward profiles: one monetizing partnerships while advancing late-stage programs, the other awaiting pivotal efficacy data on a single lead therapy. Because both companies are pre-commercial in their core pipelines, their relative performance hinges less on current earnings than on catalysts, cash runway, and scientific execution. Understanding how VIR and ZURA compare across market positioning, momentum, and risk can help traders and investors assess which profile better fits their time horizon.
VIR Overview and Recent Performance
VIR (Vir Biotechnology, Inc.) is an immunology-focused biotech advancing programs in hepatitis delta (a severe form of hepatitis B infection, or HDV) and oncology. Its pipeline centers on T-cell engagers (TCEs), engineered antibodies that direct immune T cells to attack cancer cells, plus a combination regimen of tobevibart and elebsiran for hepatitis delta.
Recent market activity has been shaped by a series of high-profile collaborations. In recent months, VIR closed a global partnership with Astellas around VIR-5500, a prostate-cancer T-cell engager, and separately granted Gilead rights to three solid-tumor TCE candidates. These deals delivered sizable upfront cash and drove a swing to a quarterly net profit, supported by roughly $239 million in collaboration revenue in its most recent quarter. The company ended that period with about $1 billion in cash and has guided that its balance sheet funds operations into the second half of 2028. Despite a longer-term share decline, VIR's year-to-date return has been strongly positive, and analyst coverage remains bullish, with a consensus price target well above its recent trading range.
ZURA Overview and Recent Performance
ZURA (Zura Bio Limited) is a clinical-stage immunology company developing dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Its lead candidate, tibulizumab, is a bispecific antibody engineered to neutralize two immune signaling proteins—interleukin-17A (IL-17A) and B-cell activating factor (BAFF)—and is being evaluated in Phase 2 studies for hidradenitis suppurativa (HS), a chronic inflammatory skin condition, and systemic sclerosis (SSc), a rare autoimmune disease.
Recent weeks have brought a steady cadence of investor-facing activity, including conference appearances and analyst updates. The company exceeded enrollment targets in both Phase 2 trials and expanded the HS study to enhance statistical power, with HS topline data expected in late 2026 and SSc data in the first half of 2027. ZURA completed a $144 million public offering earlier this year, and its cash position is expected to fund operations through at least the end of 2028. The stock trades with a market capitalization near $365 million and remains pre-revenue, with widening net losses reflecting higher research and development (R&D) spending.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated look at the platform's top-performing automated strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only the strongest and most market-suited ones earn a place in this featured section. These bots span diverse trading styles, timeframes, risk profiles, and performance statistics, with some delivering consistently high win rates and returns across varying market conditions. Because each bot follows its own strategy and ticker set, the page lets users compare signal quality and historical performance side by side. Explore the Trending AI Robots section to identify strategies aligned with your own trading objectives.
Head-to-Head Comparison
The clearest contrast is financial maturity. VIR generates collaboration revenue, holds roughly $1 billion in cash, and recently posted a quarterly profit—an unusual position for a clinical biotech. ZURA, by comparison, is pre-revenue with a smaller balance sheet and a net loss that has widened as trials advance.
The two also differ in diversification and focus. VIR spreads risk across hepatitis delta and multiple oncology assets, with several near-term clinical and regulatory catalysts. ZURA is more concentrated, with most of its value tied to tibulizumab's Phase 2 results in HS and SSc, making it more exposed to single-study outcomes. Sector exposure overlaps—both sit in biotechnology and are sensitive to clinical data and interest-rate-driven sentiment—but their therapeutic areas are distinct. On momentum, VIR's year-to-date gain has been substantially stronger, while ZURA trades nearer its 52-week low after a period of consolidation. Investors are effectively choosing between a diversified, better-capitalized pipeline story and a focused, higher-beta bet on a single mechanism.
Tickeron AI Verdict
Based on observable trend consistency, balance-sheet stability, and catalyst breadth, Tickeron's AI would likely lean toward VIR in the current environment. VIR's combination of positive momentum, a strong cash runway, multiple revenue-generating partnerships, and a diversified catalyst schedule offers a comparatively more stable trend profile. ZURA presents meaningful upside potential tied to upcoming Phase 2 data, but its narrower pipeline and pre-revenue status introduce greater variability in near-term positioning. This is a probabilistic assessment based on current market data rather than a definitive forecast, and relative positioning could shift quickly as new clinical results emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VIR is a Hold and ZURA is a Hold.
VIR's RSI Indicator penetrates overbought territory
The RSI Oscillator for VIR moved into overbought territory on November 09, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 70 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 128 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ZURA in -18.64% downward trend, declining for three consecutive days on October 23, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ZURA declined for three days, in 195 of 238 cases, the price declined further within the following month. The odds of a continued downward trend are 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZURA as a result. In 52 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for ZURA turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 41 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
The Aroon Indicator for ZURA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for ZURA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 62 cases where ZURA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZURA advanced for three days, in 153 of 188 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ZURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.989) is normal, around the industry mean (3.498). P/E Ratio (-3.652) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. ZURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIR | ||
|---|---|---|
OUTLOOK RATING 1..100 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 35 | |
P/E GROWTH RATING 1..100 | 81 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| VIR | ZURA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 77% | 1 day ago 65% |
| MACD ODDS (%) | 1 day ago 88% | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 77% | 1 day ago 72% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 75% |
| Advances ODDS (%) | 1 day ago 76% | 6 days ago 81% |
| Declines ODDS (%) | 8 days ago 81% | 18 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 81% | 1 day ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
VIR’s FA Score shows that 1 FA rating(s) are green while ZURA’s FA Score has 2 green FA rating(s).
- VIR’s FA Score: 1 green, 4 red.
- ZURA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
VIR’s TA Score shows that 7 TA indicator(s) are bullish while ZURA’s TA Score has 6 bullish TA indicator(s).
- VIR’s TA Score: 7 bullish, 2 bearish.
- ZURA’s TA Score: 6 bullish, 3 bearish.
Price Growth
VIR (@Biotechnology) experienced а +8.05% price change this week, while ZURA (@Biotechnology) price change was +1.24% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
VIR is expected to report earnings on Feb 25, 2027.
ZURA is expected to report earnings on Mar 31, 2027.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | +11.75% | ||
| BEAM - VIR | 54% Loosely correlated | +2.31% | ||
| EDIT - VIR | 54% Loosely correlated | +7.00% | ||
| DNLI - VIR | 52% Loosely correlated | +1.30% | ||
| RCUS - VIR | 51% Loosely correlated | +3.67% | ||
| PRME - VIR | 51% Loosely correlated | -7.53% | ||
More | ||||
ZURA and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZURA has been loosely correlated with ACAD. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ZURA jumps, then ACAD could also see price increases.
| Ticker / NAME | Correlation To ZURA | 1D Price Change % | ||
|---|---|---|---|---|
| ZURA | 100% | -69.68% | ||
| ACAD - ZURA | 58% Loosely correlated | -22.28% | ||
| IONS - ZURA | 51% Loosely correlated | -21.36% | ||
| VIR - ZURA | 44% Loosely correlated | +11.75% | ||
| RCUS - ZURA | 42% Loosely correlated | +3.67% | ||
| FDMT - ZURA | 40% Loosely correlated | +1.88% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| DASH.X | 47.062440 | 1.911144 | +4.23% |
| Dash cryptocurrency | |||
| TFUEL.X | 0.007542 | 0.000239 | +3.27% |
| Theta Fuel cryptocurrency | |||
| CHESS.X | 0.000074 | 0.000001 | +0.88% |
| Tranchess cryptocurrency | |||
| POLS.X | 0.050264 | 0.000390 | +0.78% |
| Polkastarter cryptocurrency | |||
| BLUR.X | 0.006594 | -0.000099 | -1.48% |
| Blur cryptocurrency | |||